Cancer Research and Treatment

Prognostic Value of Post-diagnosis Health-Related Quality of Life for Overall Survival in Breast Cancer: Findings from a 10-Year Prospective Cohort in Korea: Tran Thi Xuan Mai, Jin Hyuk Choi, Myung Kyung Lee, Yoon Jung Chang, So-Youn Jung, Hyunsoon Cho, Eun Sook Lee; Cancer Res Treat. 2019;51(4):1600-1611. Published online April 12, 2019; DOI: https://doi.org/10.4143/crt.2018.426

Purpose
We aimed to evaluate health-related quality of life (HRQOL) at 1-year post-diagnosis in breast cancer (BC) patients and its association with overall survival using data from the National Cancer Center Hospital.
Materials and Methods
Data of a BC cohort were first obtained between 2004 and 2006 and followed up. HRQOL was assessed using EORTC QLQ-C30 and BC specific module QLQ-BR23 few days after diagnosis and 1 year after that. We examined and compared the difference in the two HRQOL scores measured for each patient by the patient’s current survival status. The Cox proportional hazards model was fitted to evaluate the impact of HRQOL on survival, with adjustment for baseline HRQOL and other factors.
Results
Of 299 enrolled patients, 206 responded at 1-year post-diagnosis (80.6%) and were followed up for 11.6 years on average. At 1-year post-diagnosis, survivors had better HRQOL scores than those who died, although their health status was similar at baseline. Survivors reported significant increase 1 year after diagnosis in global health status and emotional scales. Between the groups, functional scales such as physical, role, and emotional were significantly different. Functional scales, including physical (adjusted hazard ratio [aHR], 0.70), role (aHR, 0.68), emotional (aHR, 0.72), and symptom scales, including fatigue (aHR, 1.34), dyspnea (aHR, 1.29), appetite loss (aHR, 1.24) were significantly associated with overall survival. Patients who were less worried about future health had favorable survival (aHR, 0.83).
Conclusion
Besides treatment-related symptoms, non-medical aspects at 1-year post-diagnosis, including functional well-being and future perspective, are predictive of long-term survival. Intervention to enhance physical, role, and emotional support for women soon after their BC diagnosis might help to improve disease survival outcomes afterwards.

Citations

Citations to this article as recorded by

Health-related quality of life in long-term early-stage breast cancer survivors compared to general population in Korea
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoonjung Chang, Hyunsoon Cho
Journal of Cancer Survivorship.2025; 19(2): 487. CrossRef
Lower Adherence to Lifestyle Recommendations of the World Cancer Research Fund/American Institute for Cancer Research (2018) Is Associated with Decreased Overall 10-Year Survival in Women with Breast Cancer
Jaqueline Schroeder de Souza, Luiza Kuhnen Reitz, Cândice Laís Knöner Copetti, Yara Maria Franco Moreno, Francilene Gracieli Kunradi Vieira, Patricia Faria Di Pietro
Nutrients.2025; 17(6): 1001. CrossRef
Prognostic value of cancer-related fatigue at the end of radiotherapy for overall survival ≥ 10 years in women with breast cancer
Philipp Heumann, Axel Benner, Sabine Behrens, Jenny Chang-Claude, Petra Seibold
Breast Cancer Research.2025;[Epub] CrossRef
Long-term trajectory of postoperative health-related quality of life in young breast cancer patients: a 15-year follow-up study
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho
Journal of Cancer Survivorship.2023; 17(5): 1416. CrossRef
Associations between health-related fitness and quality of life in newly diagnosed breast cancer patients
Kerry S. Courneya, Ki-Yong An, Fernanda Z. Arthuso, Gordon J. Bell, Andria R. Morielli, Jessica McNeil, Qinggang Wang, Spencer J. Allen, Stephanie M. Ntoukas, Margaret L. McNeely, Jeff K. Vallance, S. Nicole Culos-Reed, Karen Kopciuk, Lin Yang, Charles E.
Breast Cancer Research and Treatment.2023; 199(3): 533. CrossRef
Quality of life and cost-effectiveness of different breast cancer surgery procedures: a Markov decision tree-based approach in the framework of Predictive, Preventive, and Personalized Medicine
Hon-Yi Shi, Chiu-Hui Li, Yen-Chen Chen, Chong-Chi Chiu, Hao-Hsien Lee, Ming-Feng Hou
EPMA Journal.2023; 14(3): 457. CrossRef
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
Clinical and Translational Oncology.2023; 25(12): 3492. CrossRef
Illness Perception and Quality of Life in Patients with Breast Cancer
Edyta Ośmiałowska, Jakub Staś, Mariusz Chabowski, Beata Jankowska-Polańska
Cancers.2022; 14(5): 1214. CrossRef
Psychometric Evaluation of the Korean Version of the Functional Assessment of Chronic Illness Therapy-Fatigue
Won-Gyeom LEE, Hee-Ju KIM
Journal of Nursing Research.2022;[Epub] CrossRef
Digital and Interactive Health Interventions Minimize the Physical and Psychological Impact of Breast Cancer, Increasing Women’s Quality of Life: A Systematic Review and Meta-Analysis
Esteban Obrero-Gaitán, Irene Cortés-Pérez, Tania Calet-Fernández, Héctor García-López, María del Carmen López Ruiz, María Catalina Osuna-Pérez
Cancers.2022; 14(17): 4133. CrossRef
Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors
Thi Xuan Mai Tran, So-Youn Jung, Eun-Gyeong Lee, Heeyoun Cho, Na Yeon Kim, Sungkeun Shim, Ho Young Kim, Danbee Kang, Juhee Cho, Eunsook Lee, Yoon Jung Chang, Hyunsoon Cho
Cancer Research and Treatment.2022; 54(4): 1065. CrossRef
Cancer-related Fatigue in Breast Cancer Survivors: A Review
Ana Ruiz-Casado, Alejandro Álvarez-Bustos, Cristina G. de Pedro, Marta Méndez-Otero, María Romero-Elías
Clinical Breast Cancer.2021; 21(1): 10. CrossRef
Cancer outcomes research—a European challenge: measures of the cancer burden
Mette Kalager, Hans‐Olov Adami, Pernilla Lagergren, Karen Steindorf, Paul W. Dickman
Molecular Oncology.2021; 15(12): 3225. CrossRef
Weight Change in Post-Menopausal Women with Breast Cancer during Chemotherapy—Perspectives on Nutrition, Activity and Bone Metabolism: An Interim Analysis of a 5-Year Prospective Cohort
Kristian Buch-Larsen, Trine Lund-Jacobsen, Michael Andersson, Peter Schwarz
Nutrients.2021; 13(8): 2902. CrossRef
Unmet supportive care needs of survival patients with breast cancer in different cancer stages and treatment phases
Ying-Hsiang Chou, Vivian Chia-Rong Hsieh, XianXiu Chen, Ting-Yi Huang, Shwn-Huey Shieh
Taiwanese Journal of Obstetrics and Gynecology.2020; 59(2): 231. CrossRef
Quality of life in advanced cancer patients
Satvik Khaddar
Cancer Research, Statistics, and Treatment.2020; 3(1): 117. CrossRef

8,675 View
189 Download
15 Web of Science
16 Crossref

Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes: Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunee Yim, Seung Hee Kang; Cancer Res Treat. 2017;49(2):484-493. Published online August 23, 2016; DOI: https://doi.org/10.4143/crt.2016.246

Abstract PDF PubReader ePub

Purpose
The effects of biological subtypes within breast cancer on prognosis are influenced by age at diagnosis. We investigated the association of young age with locoregional recurrence (LRR) between patients with luminal subtypes versus those with nonluminal subtypes.
Materials and Methods
Medicalrecords of 524 breast cancer patientswith positive lymph nodes between 1999 and 2010 were reviewed retrospectively. All patients received curative surgery and adjuvant chemotherapy based on contemporary guidelines. Radiation was delivered for patients who underwent breast conserving surgery or those who had four or more positive lymph nodes after mastectomy. Adjuvant hormone therapywas administered to 413 patientswith positive hormone receptors according to their menstrual status.
Results
During median follow-up of 84 months, the 10-year locoregional recurrence-free survival rate (LRRFS) was 84.3% for all patients. Patients < 40 years showed significantly worse 10-year LRRFS than those ≥ 40 years (73.2% vs. 89.0%, respectively; p=0.01). The negative effect of young age on LRRFS was only observed in luminal subtypes (69.7% for < 40 years vs. 90.8% for ≥ 40 years; p < 0.01). Multivariate analysis using luminal subtypes ≥ 40 years as a reference revealed luminal subtypes < 40 years were significantly associated with increased risk of LRR (hazard ratio, 2.33; p < 0.01).
Conclusion
Young breast cancer patients with positive lymph nodes had a higher risk of LRR than those aged ≥ 40 years. This detrimental effect of young age on LRR was confined in luminal subtypes.

Citations

Citations to this article as recorded by

Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer
Cindy Im, Hasibul Hasan, Emily Stene, Sarah Monick, Ryan K. Rader, Jori Sheade, Heather Wolfe, Zhanni Lu, Logan G. Spector, Aaron J. McDonald, Vikki Nolan, Michael A. Arnold, Miriam R. Conces, Chaya S. Moskowitz, Tara O. Henderson, Leslie L. Robison, Greg
Nature Communications.2025;[Epub] CrossRef
The disparities in prognostic prediction and annualized hazard function in different molecular subtypes between young Chinese and White American women with breast cancer
Yuanyuan Zeng, Jun Wang, Xiaorong Zhong, Zhongzheng Xiang, Tian Yang, Siting Yu, Zelei Dai, Ningyue Xu, Lei Liu
Frontiers in Oncology.2023;[Epub] CrossRef
Comparing the Prognoses of Breast-Conserving Surgeries for Differently Aged Women with Early Stage Breast Cancer: Use of a Propensity Score Method
Shurui Bao, Guijin He, Pranshu Sahgal
The Breast Journal.2022; 2022: 1. CrossRef
The different prognostic impact of age according to individual molecular subtypes in breast cancer
Nam Hee Kim, Hye Won Bang, Yong Hwa Eom, Seung Hye Choi
Annals of Surgical Treatment and Research.2022; 103(3): 129. CrossRef
Do prognosis and clinicopathological features differ in young early-stage breast cancer?
Akif Enes Arikan, Halil Kara, Onur Dülgeroğlu, Esin Nur Erdoğan, Emir Capkinoglu, Cihan Uras
Frontiers in Surgery.2022;[Epub] CrossRef
Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: long-term results using propensity score adjustment method
Lize Wang, Yingjian He, Jinfeng Li, Tianfeng Wang, Yuntao Xie, Zhaoqing Fan, Tao Ouyang
Breast Cancer Research and Treatment.2020; 183(3): 717. CrossRef
The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis
Shibin Cai, Wenjia Zuo, Xunxi Lu, Zongchao Gou, Yi Zhou, Pengpeng Liu, Yin Pan, Shuzheng Chen
Frontiers in Oncology.2020;[Epub] CrossRef
Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy
Tae In Yoon, Ui-Kang Hwang, Eui Tae Kim, SaeByul Lee, Guiyun Sohn, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Seonok Kim, Sei Hyun Ahn, Hee Jeong Kim
Breast Cancer Research and Treatment.2017; 165(2): 311. CrossRef

11,951 View
295 Download
9 Web of Science
8 Crossref

Development and Test of an Information Needs Scale for Outpatients Undergoing Chemotherapy: Eun Hyun Lee, Jin Hyuk Choi, Ho Yeong Lim, Mi Sook Seo, Hugh C Kim; Cancer Res Treat. 2002;34(2):97-103. Published online April 30, 2002; DOI: https://doi.org/10.4143/crt.2002.34.2.97

Abstract PDF

PURPOSE
The purpose of this study was to develop and test an Information Needs Scale for Korean outpatients undergoing chemotherapy (INS-C).
MATERIALS AND METHODS
Thirty-three items of the INS-C had content validity based upon findings in the literature and the experiences of expert oncology physicians and nurses. Each item consisted of a five-point Likert scale from 1 (don't want to know) to 5 (want to know very much). The items were administered to 175 Korean outpatients undergoing chemotherapy. The data obtained was analysed using a factor analysis for construct validity and Cronabch's alpha for internal consistent reliability.
RESULTS
From the factor analysis, six subscales were derived significantly. The six subscales explained 64.62% of the variance. The subscales were named Side-Effects/Investigative Tests (9 items), Spread of Disease (4 items), Financial Cost (2 items), Treatment (7 items), Activities/ Eating (6 items), and Interrelationships/Support (5 items). The Cronbach's alpha of the total INS-C was .95, and the alpha of the subscales ranged from .77 to .91.
CONCLUSION
The present study suggests that the INS-C is a reliable and valid instrument to measure the information needs of outpatients undergoing chemotherapy. Health professionals caring for patients with cancer should assess the informational needs of their patients using a reliable and valid instrument and be prepared to provide accurate information.

Citations

Citations to this article as recorded by

Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care
Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim
Journal of Korean Academy of Nursing.2010; 40(4): 551. CrossRef

3,571 View
34 Download
1 Crossref

The Efficacy and Safety of Docetaxel in Patients with Anthracychne pretreated Metastatic Breast Cancer: A Multicenter Phase II Study: Joong Bae Ahn, Kwang Yong Shim, Joon Oh Park, Hei Chul Jung, Nae Choon Yoo, Hyun Cheol Chung, Joo Hang Kim, Jin Hyuk Choi, Hyun Soo Kim, Hugh Chul Kim, Woo Kun Kim, Jae Kyung Roh; J Korean Cancer Assoc. 2000;32(2):235-243.

Abstract PDF: PURPOSE
Tbis phase II study was performed to evaluate the efficacy and safety of docetaxel in patients with anthracycline-pretreated metastatic breast cancer (MBC).
MATERIALS AND METHODS
From September 1996 to January 1998, 27 patients with metastatic breast cancer from 31 to 63 years of age with a performance status of 0 to 2 were registered in the phase II trial. All patients had metastatic breast cancer which had progressed or relapsed 2 during or after treatment with an anthracycline-based regimen. Docetaxel 75 mg/m2 was ad- ministered over 1 hour every 21 days until disease progression was documented or until toxic effects precluded further therapy. All patients received dexamethasone orally at the dose of 16 mg on days -1, 0, 1 of each cycle.
RESULTS
Objective responses were seen in 9 of 25 assessable patients (two complete and seven partial responses), with an overall objective response rale of 36%. The median duration of response was 36 weeks (range 19.0~40.5). The median time to progression and survival duration were 17.5 and 69 weeks, respectively, for assessable patients. One hundred fifty cycles (median, five) of docetaxel were administered. Among 27 patients assessable for toxicity, the following side effects were reported: nadir neutropenia grade 3 (4 patients) and grade 4 (22 patients); grade 2 stomatitis (6 patients); grade 2 alopecia (5 patients); grade 2 to 3 neurosensory toxicity (4 patients); no hypersensitivity reaction; mild fluid retention (4 patients).
CONCLUSION
Docetaxel is an active agent in patients with antracycline-pretreated metastatic breast cancer. Docetaxel was associated with severe but reversible neutropenia. Dexamethasone prevented hypersensitivity reactions and appeared to ameliorate fluid retention.

3,606 View
27 Download

Intracavitary 166 Holmium - chitosan Complex Therapy in Patients with Malignant Peritoneal or Pleural Effusions: Do Yeun Cho, Hyun Soo Kim, Joon Seong Park, Cheol Kweon Jeong, Jin Hyuk Choi, Ho Yeong Lim, Chan Hee Park, Mi Son Chun, Young Mi Kim, Kyung Bae Park, Hugh Chul Kim; J Korean Cancer Assoc. 1999;31(6):1297-1306.

Abstract PDF: PURPOSE
Most malignant peritoneal or pleural effusions caused by advanced malignancy are unresponsive to systemic chemotherapy except for chemotherapy sensitive tumors, and they are equally ineffective to regional therapy or radiotherapy. Thus, for the purpose of palliating the symptoms related to malignant effusion and to reduce fluid reaccumulations, we evaluated the therapeutic feasibility and efficacy of intracavitary ' Ho-CHICO (chito- san complex) instillation for intractable malignant effusions.
MATERIALS AND METHODS
Thirty one patients with cytologically or pathologically proven malignant effusions underwent intracavitary 166Ho-CHICO therapy from May 1996 to March 1998 at Ajou University Hospital. The subjective and objective responses were evaluated 4 weeks after the treatment, including the changes of symptoms, weight, abdominal girth, doses of diuretics, frequencies and amounts of repeat aspirations for fluid reaccumulations, and imaging studies of chest radiograph and ultrasounds.
RESULTS
The response rates treated with Ho-CHICO were 50% in patients with peritoneal effusion and 46% in patients with pleural effusion (overall 49%). The response rates between 166Ho-CHICO doses of 50-80 mCi and 90-100 mCi were similar (50% vs 47%). Response rate of 70% was noted in patients with even distribution of radioisotope on the post-therapy scan, but, the response rate was lower in cases with focal (44%) and uneven (29%) distribution pattern. There was no difference in response by the effusion sites. All patients tolerated intracavitary 166Ho-CHICO instillation well, although the majority of patients experienced Grade I/II side effects such as pain, fever, weakness and dyspnea. But, no serious complications of Grade lII or IV degree were observed with 166Ho-CHICO therapy.
CONCLUSION
Intracavitary 166Ho-CHICO instillation was clinically efficacious in controlling malignant effusions without a significant toxicity seen with conventional sclerotic therapy. The therapeutic modality appeared to offer similar benefits obtained with the conventional intracavitary therapy.

2,836 View
14 Download

Therapeutic Outcome and Prognosis in Dlderly Patients with Non - Hodgkin's Lymphoma: Jee Sook Hahn, Jin Hyuk Choi, Seung Tae Lee, Yoo Hong Min, Yun Woong Ko; J Korean Cancer Assoc. 1999;31(2):320-330.

Abstract PDF: PURPOSE
The prognosis of non-Hodgkins lymphoma (NHL) in elderly patients seems to be poorer than that in patients aged less than 60 years. This may be due to the lower tolerance for combination chemotherapy in the elderly. Aggressive combination chemo-therapy, which is the treatment of choice in intermediate and high grade NHL of adulthood, may be associated with unpredictab1y severe and lethal toxicity and worsened quality of life in the elderly. We investigated the treatment responses, toxicities and prognostic factors of NHL in elderly patients treated with combination chemotherapy.
MATERIALS AND METHODS
We treated 116 elderly (>60 yrs) patients with NHL between January 1986 and June 1996 with adriamycin-containing regimens, such as CHOP (cyclo- phosphamide, adriamycin, vincristine, prednisolone), BACOP (bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone), and mBACOP (methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone). Patients in this study ranged from 60 to 81 (median 67) years of age. Fifty-five percent of patients were in stage I or II and the rest (45%) were in stage III or IV. The histologic grade was predominantly (91%) of intermediate and high grade type.
RESULTS
The treatment responses were complete (CR) in 55% and partial (PR) in 25%. The median durstion of CR was 32 (3-132) months. The CR rate was significantly higher in patients treated with RDI (relative dose intensity) > 75% than that in the patients treated with RDI < 75% (p 0.003), but there was no significant difference in CR rate between treatment regimens (p-0.38). At a median follow up of 48-months (range, 12 to 132 months), the estimated 5-year ovetall survival was 46%. Ann Arbor Stage (I, II vs III, IV), ECOG performance (0-1 vs 2-3), RDI (>75% vs <75%) and the treatment response were important prognostic factors in the univariate analysis, and the treament response (CR vs non-CR) was the only independent prognostic parameter in the multivariate analysis. The most frequent and severe toxicity associated with chemotherapy was infection with or without neutropenia. The rate of severe infection was significantly decreased in the patients supported with G/GM-CSF but not in the dose-reduction group (RDI<75% vs >75%).
CONCLUSION
Our data suggests that achievement of the CR after combination chemotherpy is the most important prognostic factor in the elderly patients with NHL. Suboptimal chemotherapy (RDI<75%) reduced the complete remission rate without reducing the likelihood of developing severe toxicities. Optimal chemotherapy with supportive cares involving the use of hematopoietic growth factors may be needed to improve the treatment response and the survival in the elderly patients with aggressive NHL.

2,796 View
17 Download

Effect on Malignant Phenotype of Gastric Cancer Cell Line after p53 Gene Transduction: Sun Young Rha, Tae Soo Kim, Sook Jung Jeong, Joong Bae Ahn, kwang Yong Shim, Soo Jung Kong, Hwa Young Lee, Nae Choon Yoo, Jin Hyuk Choi, Ho Young Lim, Joo Young Lim, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung; J Korean Cancer Assoc. 1998;30(3):508-520.

Abstract PDF: PURPOSE
To evaluate the effect of wild type p53 gene transduction on the malignant phenotypes for metastasis in gastric cancer, we compared the biological phenpotypes of gastric cancer cell lines based on p53 gene status. Then, after retrovirus-mediated wild-type p53 gene transduction, we compared those phenotypes among parent YCC-3 cell line, vector transduced YCC-3v cell line and a clone of YCC-3C3. MATERIAL AND METHODS: Four human gastric cancer celi lines were used; YCC-l(mutant), YCC-2(wild), YCC-3(mutant) and AGS(wild). DNAs of the cell lines were analyzed to evaluate the mobility shift with PCR-SSCP. Tumorigenecity and proliferation were evaluated by soft agar assay and proliferation assay. Migratory capacity was measured by adhesion assay and Boyden chamber assay. p53 protein expression was measured by Western blot analysis and VEGF, WAF-1 were measured by ELISA assay. Angiogenic activity was measured by cross-feeding assay and cell cycle analysis was performed by flowcytometry. In vivo tumorigenicity was measured by xenograft in nude mice.
RESULTS
YCC-3 cell line with mutant p53 gene expressed all the phenotypes for the metastasis such as tumorigenicity, migration and angiogenesis. In a stable clone of YCC-3C3, no differences were found in proliferation, cell cycle and WAP-1 expression when compared to those of the control YCC-3v and parent YCC-3 cell line, even if increased p53 protein production was found by Western blot analysis. However, both in vitro and in vivo tumorigenicity were decreased in a stably transduced YCC-3C3 clone. The adhesive capacity was also decreased in YCC-3C3 clone whereas the endothelial cell growth stimulatory effect and VEGF production showed no difference compared to those of the YCC-3v cell line.
CONCLUSION
Wild-type p53 gene transduction in gastric cancer cell line decreased tumorigenicity which resulted from decreased colony forming activity and adhesive capacity but not formed changes of angiogenic activity. This suggested the possible application of anti- metastasis strategy with p53 gene therapy in gastric cancer.

3,174 View
40 Download

Restoration of Wild - type p53 Induces Chemo-sensitization in the Gastric Cancer Cell Line with Mutant p53: Ho Young Maeng, Sun Young Rha, Byung Soh Min, Yong Bae Kim, Hyun Joo Kwak, Tae Soo Kim, Kyu Hyun Park, Nae Choon Yoo, Ho Young Lim, Jin Hyuk Choi, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung; J Korean Cancer Assoc. 1998;30(3):497-507.

Abstract PDF: PURPOSE
It has been theorized that p53 may be involved in the sensitivity to chemotherapeutic agents. We evaluated the chemosensitivity of wild p53 after transduction into gastric cancer cell lines with mutant p53.
MATERIALS AND METHODS
YCC-3(parent cell line with mutant p53), YCC-3v(parent cell line transduced with vector alone) and YCC-3C3(clone with wild p53) cell lines were used in this study. p53 protein expression was measured by ELISA assay. Tumorigenicity and drug sensitivity were evaluated by soft agar and proliferation assay, respectively. Cell cycle analysis was performed by flowcytometry. Telomerase activity was measured by TRAP assay and terminal restriction fragment(TRF) length was measured after Southern blot analysis.
RESULTS
Even though p53 production from the YCC-3C3 cell line was three times higher than those of YCC-3 and YCC-3v cell lines, the cell cycle was the same in these three cell lines. In the YCC-3C3 cell line, drug sensitivity to etoposide and cisplatin was increased when we compared it to those of the YCC-3v cell line(etoposide, 50% versus 83%; cisplatin, 67% versus 83%). However, there was no chemo-sensitization effect with vincristine, vinblastine and carboplatin. After exposure to cisplatin, a G0/G1 check-point effect was found in the YCC-3C3 cell line, but not in the YCC-3v cell line. No differences were found in telomerase activity, TRFs length or DNA fragmentation between the YCC-3v and YCC-3C3 cell lines after cisplatin treatment.
CONCLUSION
Wild-type p53 gene transduction in the gastric cancer cell line induced sensitization to the cytotoxicity of etoposide and cisplatin. This suggests the possible application of combined chemo-gene therapy with an EP regimen and wild-type p53 in gastric cancer patients with p53 mutation.

3,212 View
22 Download

Gene Transfer Effects of Thymidine Kinase Gene of Herpes Simplex Type 1 on Ganciclovir Cytotoxicity in Gastric Cancer Cell Line: Jae Kyung Roh, Soo Jung Gong, Joo Hang Kim, Hyo Dong Um, Nae Chun Yoo, Jin Hyuk Choi, Jae Jin Song, Sun Young Rha, Hyun Cheol Chung, Jin Sik Min, Byung Soo Kim; J Korean Cancer Assoc. 1998;30(1):20-30.

Abstract PDF: PURPOSE
Gastric cancer is the most common malignancy in Korea. Although treatment such as surgery, chemotherapy, and immunotherapy has greatly improved, the mortality rate of gastic cancer is still high, A new therapeutic trial is necessary to improve the cure rate of gastric cancer. Therefore we investigated the pre-clinical significance of HSV-tk gene therapy using retroviral vector for gastric cancer cell lines.
MATERIALS AND METHODS
LNC/HSV-tk retroviral vector and PA317/LNC/HSV-tk producer cell line were constructed. HSV-tk gene transduction and expression were detected by PCR. An in vitro ganciclovir(GCV) sensitivity test was performed by MTT assay. To evaluate in vivo GCV sensitivity, GCV was intraperitoneally injected after tumor formation in the nude mice. Bystander effect was observed in vitro MTT assay using YCC- S-2 cell line and in vivo using N87 and YCC-S-2 cell lines.
RESULTS
The in vitro GCV sensitivity test showed that the growth inhibition was 30~32% with 0.5 uM GCV and 52~77% with 500 uM GCV in the HSV-tk transduced cell line in comparison with 0- 5% with 0.5 and 500 uM GCV in the parent cell line. The in vivo GCV administration showed that the tumors induced by HSV-tk transduced N87 cell line and YCC-S-2 cell line decreased completely, while the tumors with the parent cell lines continued to grow in nude mice. We observed no tumor cells in tissue specimen of the tumor induced by the N87/HSV-tk cell line after. GCV administration. In vitro and in vivo bystander effects were observed in HSV-tk/GCV system due to the resultant cell death exceeding the proportion of HSV-tk transduced cells in the mixtures of HSV-tk transduced and parent cells.
CONCLUSION
HSV-tk transduced gastric cancer cell lines showed sensitivity to GCV and a bystander effect was observed. These results suggested that HSV-tk/GCV system should be evaluated in the clinical settings.

2,762 View
20 Download

Therapeautic effect of hepatic arterial infusion of cisplatin in primary hepatocelluar carcinoma: Jae Yong Cho, Jin Hyuk Choi, Nae Choon Yoo, Ho Young Lim, Joo Hang Kim, Jae Kyung Roh, Jong Tae Lee, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(6):865-872.

Abstract PDF: No abstract available.

2,589 View
13 Download

Four cases of primary malignant lymphoma of the breast: Jin Ahn Kim, Jin Hyuk Choi, Jae Yong Cho, Hee Yong Moon, Bum Soo Kim, Ho Young Lim, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(5):773-779.

Abstract PDF: No abstract available.

2,631 View
13 Download

Phase II clinical trial of recombinant human granulocyte colony-stimulating factor(fhG-CSF)(KRN8601) in advanced cancer patients with myelosuppression after chemotherapy: Jae Kyung Roh, Jin Hyuk Choi, Kyung Hee Lee, Hye Ran Lee, Nae Choon Yoo, Joo Hang Kim, Byung Soo Kim, Ho Young Lim; J Korean Cancer Assoc. 1993;25(5):725-735.

Abstract PDF: No abstract available.

2,783 View
15 Download

The role of combined induction chemotherapy and radical radiation therapy in the treatment of advanced nasopharyngeal cancer: Jin Hyuk Choi, Jae Kyung Roh, Ho Young Lim, Hyun Chul Jung, Nae Choon Yoo, Shin Ki Ahn, Eun Hee Koh, Joo Hang Kim, Chang Ok Seo, Kwi Un Kim, Joon Kyoo Roh, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(3):403-416.

Abstract PDF: No abstract available.

2,916 View
12 Download

p53 gene mutation in hepatocellular carcinoma from Korean patients and in established hepatocellular carcinoma cell lines: Joo Hang Kim, Joo Bae Park, Mitsudomi Tetsuya, Jung Joo Choi, Nae Choon Yoo, Jin Hyuk Choi, Ho Young Lim, Jae Kyung Roh, Kyung Sik Lee, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(3):359-367.

Abstract PDF: No abstract available.

2,522 View
13 Download

Efficacy of recombinant human granulocyte colony-stimulating factor(neutrogin) for chemotherapy induced neutropenia in patients with advanced lung carcinoma: Nae Choon Yoo, Joo Hang Kim, Yi Young Lee, Se Kyoo Kim, Sung Kyoo Kim, Won Young Lee, Bong Soo Cha, Jin Hyuk Choi, Ho Young Lim, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(2):236-246.

Abstract PDF: No abstract available.

2,911 View
16 Download

Effects of verapamil, tamoxifen and cyclosporin A for the modulation of multidrug resistance in human lung cancer lines: Joo Hang Kim, Byung Soo Kim, Jung Joo Choi, Kyung Mi Kim, Nae Choon Yoo, Jin Hyuk Choi, Ho Young Lim, Jae Kyung Roh, Kyung Sik Lee, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(2):225-235.

Abstract PDF: No abstract available.

2,490 View
14 Download

Efficacy of clodronate(ostac) on bone metastases in malignancy: Joo Hang Kim, Ho Young Lim, Nae Choon Yoo, Sun Young Rah, Jin Hyuk Choi, Eun Hee Koh, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1993;25(1):85-91.

Abstract PDF: No abstract available.

2,544 View
15 Download

The influence of pathologic grade on adenoid cystic carcinoma: Ki Yong Kim, Jin Hyuk Choi, Ho Young Rhim, Hyun Cheol Chung, Eun Hee Koh, Joo Hang Kim, Jae Kyung Rho, Ki Bum Lee, Byung Soo Kim; J Korean Cancer Assoc. 1992;24(4):516-523.

Abstract PDF: No abstract available.

2,856 View
13 Download

Intrapleural instillation of OK-432 for malignant pleural effusion: Ho Yeong Lim, Joo Hang Kim, Young Hwan Park, Hyun Cheol Chung, Joung Ju Choi, Seoung Goo Choi, Ho Geun Kim, Jin Hyuk Choi, Nae Chun Yoo, Eun Hee Koh, Joon Chang, Jae Kyung Roh; J Korean Cancer Assoc. 1992;24(1):47-55.

Abstract PDF: No abstract available.

2,774 View
14 Download

Efficacy of ONDANSETRON(GR38032F) for the control of cisplatin induced nausea and vomiting in patients with advanced malignancies: Jae Kyung Roh, Nae Chun Yoo, Jin Hyuk Choi, Hyun Cheol Chung, Ho Young Lim, Eun Hee Koh, Joo Hang Kim, Byung Soo Kim; J Korean Cancer Assoc. 1991;23(4):814-820.

Abstract PDF: No abstract available.

2,587 View
13 Download

5-fluorouracil and low dose leucovorin in advanced colorectal carcinoma: Ho Yeong Lim, Hyun Cheol Chung, Jin Hyuk Choi, Nae Chun Yoo, Dong Lip Kim, Eun Hee Koh, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1991;23(3):563-570.

Abstract PDF: No abstract available.

2,725 View
14 Download

A phase II trial of combined sequential FP (5-FU+cisplatin) chemotheraphy and radiotherapy in locally advanced unresectable esophageal cancer: Jong Won Ha, Hyun Cheol Chung, Dong Lip Kim, Jin Hyuk Choi, Nae Choon Yoo, Eun Hee Koh, Joo Hang Kim, Jae Kyung Roh, Gwi Eon Kim, John Kyu Loh Juhn, Byung Soo Kim; J Korean Cancer Assoc. 1991;23(2):307-314.

Abstract PDF: No abstract available.

2,513 View
14 Download

Phase II trial of sequential VP-16, cisplatin combination chemotherapy and radiotherapy for locally advanced (stage III) non-small cell lung cancer: Hyun Cheol Chung, Jin Hyuk Choi, Yoon Seok Chung, Dong Jip Kim, Young Sik Lee, Joon Chang, Eun Hee Koh, Joo Hang Kim, Jae Kyung Roh, Sung Kyu Kim, Won Young Lee, Gwi Eon Kim; J Korean Cancer Assoc. 1991;23(1):131-139.

Abstract PDF: No abstract available.

2,956 View
14 Download

Phase II trial of 5-FU, etoposide, cisplatin (FEP) combination chemotherapy in unresectable non-small cell lung cancer: Jin Hyuk Choi, Hyun Cheol Chung, Dong Jip Kim, Je Yol Oh, Joon Chang, Eun Hee Koh, Joo Hang Kim, Jae Kyung Rho, Sung Kyu Kim, Won Young Lee, Gwi Eon Kim, John Kyu Loh Juhn; J Korean Cancer Assoc. 1991;23(1):120-130.

Abstract PDF: No abstract available.

2,735 View
17 Download

A Report of Two Cases of Leptomeningeal Carcinomatosis on Stomach Cancer: Dong Lip Kim, Jae Kyung Roh, Jin Hyuk Choi, Hyun Cheol Chung, Yong Jun Park, Won Ho Kim, Seung Min Kim, Jin Sik Min, Kwang Hwa Park, Chang Ok Suh, Jun Kyu Loh, Byung Soo Kim; J Korean Cancer Assoc. 1989;21(1):141-150.

Abstract PDF: Meningeal carcinomatosis is an important neurologic complication. It is increasingly being recog- nized as a cause of neurologic disability in life. But stomach cancer has rarely been reported to be a cause of meningeal carcinomatosis. We reported two cases of 46-year-old male and 56-year-oldfemale who were diagnosed gastric cancer by biopsy under fiberoptic gastroscopy. These two cases of stomach cancer with meningeal invasion revealed malignant cells in their cerebrospinal fluid by repeated lumbar puncture. After diagnosis, they were treated radiation therapy in whole brain field. And, now, we have the plan of intrathecal chemotherapy.

2,775 View
21 Download

Induction Chemotherapy and Surgery in Locally Advanced Stomach Cancer Showing Pancreas Involvement: Kyung Hee Lee, Jin Hyuk Choi, Sun Young Rha, Hye Ran Lee, Nae Chun Yoo, Ho Yeong Lim, Hyun Cheol Chung, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1994;26(3):377-385.

Abstract PDF: Gastric cancer is the most common malignancy in Korea. Cure for patients with gastric carcinoma can be achieved only by radical surgery. From August 1988 to May 1992, 25 patients with locally advanced unresectable gastric cancer received 5-FU(Fiuorouracil) + adriamydn + mitomycin-c or 5-FU + cisplatin based induction chemotherapy before surgem. The partial response rate after me- dian 3 cycles of induction cemotherapy was 52%, stable disease 12%, progressive disease 36%. Gastric resection was performed in 18 patients(72%); 13 patients(52%) underwent radical surgery and 5 patients(20%) underwent palliative surgery. Median survival of the patients who underwent cura- tive and palliative surgery was 24. 2 and 27 months, respectively. However, median survival of the patient who didnt undergo any surgery was only 6.5 months. The difference of median survival between curative surgery and none surgery group were significant statistically(P<0.03). Side effects of induction chemotherapy were acceptable and there were no life threatening toxicities In this study, half of the patients can undergo curative surgery after induction chemotherapy. We observe the long term survival in some patients after induction chemotherapy and surgery in loco-regionally advanced gsstric cancer. This therapeutic approch for the locally advanced stomach cancer seems to be feasible. But, prospective tandomized clinical trial is warranted in the future.

2,815 View
14 Download

Phase 1b Clinical Trial and Pharmacokinetic Evaluation of Recombinant Human Granulocyte - Macrophage Colony: Jae Kyung Roh, Jin Hyuk Choi, Hyung Keun Roh, Sun Young Rha, Kyung Hee Lee, Hye Ran Lee, Jee Sook Hahn, Pum Soo Kim, Byung Soo Kim; J Korean Cancer Assoc. 1994;26(3):495-510.

Abstract PDF: To define the clinical safeties and hematologic effects of subcutaneously administered yeast- derived recombinant human granulocyte-macrophage colony stimulatina factor(rh GM-CSF, LBD-005h and to determine the maximally tolerated dose(MTD) and the pharmacokinetics. Sngle arm open non-randomized phase Ib study was carried in 15 cancer patients#(14 patients evaluable) with chemotherapy induced bone marrow depression. Rh GM-CSF by once-daily subcutaneous administration to groups of 3-6 patients at doses of 50, 100, 150, 250, 350, 500, 700 ug/m/d for 10 consecutive days was escalated unless greater than WHO grade III toxicites were observed. Intrapatient dose escalation was permitted. Clinical safeties and toxicities were observed with frequent hematologic monitering. Blood and urine were collected on day 1, and 8 of rh GM-CSF administration to evaluate the parmacokinetic parameters. Of the 15 enrolled patients, 14 patients were evaluable. Male to female ratio was 8: 6 with median age 32 y-o(10~70 y-o). Seven patients had osteosarcoma, 2 malignant lymphoma, 2 gastric carcinoma, 2 lung cancer and 1 had uterine leiomyosarcoma. The total administered cycles of rh GM-CSF were 24. At each dose step, 3 patients were treated with exception of 6 patients at 500 ug/m/d dose. At all the doses administered, fever and flue-like syndrome were common side effects. Grade I fever and flue-like syndrome 50~150 pg/m dose, and grade II fever flue- like syndrome were observed at the dose of grater than 250 u/m(2)/d dose. Even at the 700 ug/m(2)/ d dose, no greater than grade III toxicities were observed. Leucocytosis were dose dependent with 120-480% increment of baseline. Pharmacokinetic parameters are as follows; Cmax were dose dependent(0.42-11.7 ng/ml) with 2-4 hours of Tmax. AUC were also dose dependent(3.93~87.9ng.hr/ml) with sustained serum levels(0.2-2ng/ml) up to 12 hours after rh GM-CSF administration. Urinary excretion(0-24 hours) after GM-CSF was less than 1% of administered dose. Yeast-derived rh GM-CSF induces leucocytosis in the dose range of 150~500ug/m(2)/d with tolerable side effects. Subcutaneously administered rh GM-CSF has sustained serum levels up to 12 hours after administration. The doses of 150-500 ug/m/d would be appropriated for the further trials.

2,849 View
14 Download

Prognostic Significance of Proliferating Cell Nuclear Antigen ( PCNA: Ho Yeong Lim, Joo Hang Kim, Hyun Cheol Chung, Hyo Dong Um, Jin Hyuk Choi, Byung Soo Kim, Dong Hwan Shin, Jae Kyung Roh, Byung Soo Kim; J Korean Cancer Assoc. 1995;27(1):18-28.

Abstract PDF: Proliferatina cell nuclear antigen(PCNA) is known to be closely correlated with DNA synthesis and cell proliferation. Proliferative activities of tumors have recently been consid- ered as one of important prognostic factors in a variety of human cancers. A total of 195 gastric carcinomas was evaluated with immunohistochemical study, using an- tibody(PC 10) with special reference to the correlation between PCNA expression and progno- sis. PCNA expression was assessed semi-quantitatively based on the proportion of tumor cells with immunostained nuclei. There was no significant correlation between PCNA expression and clinicopathological variables such as age, sex, tumor site, size, histologic grade, tumor stage, or the presence of lymph node metastases. To analyse survival, we evaluated disease-free survival and overall survival according to the extent of PCNA expression. No significant correlations between PCNA expression and both disease-free survival and overall survival were found. In conclusion, PCNA expression assessed by semi-quantitative PCNA grading system was not a significant prognostic factor in gastric carcinoma.

2,745 View
13 Download

The Effect of Perioperative Blood Transfusion on the Prognosis of Colorectal Cancer Patients: Hee Jung Choi, Jin Hyuk Choi, Soon Nam Lee, Eung Bum Park, Kyung Ja Lee; J Korean Cancer Assoc. 1995;27(3):403-411.

Abstract PDF: Except for the weli known prognostic factors of cancer, the studies that perioperative transfusion of surgically resectable cancer could influence the survival of cancer patients were continued to be investigated. The explanation of deleterious effects of transfusion has been supported by the results that the incidences of renal allograft rejection were decreased by pretransplantation tranafusion, and transfusion resulted in changes of mononuclear cell function and inhibited natural killer cell activity. But definite proof of this adverse eifect has not been settled. We investigated whether perioperative transfusion can diminish the eurvival rate of patients with colorectal cancer and transfusion itself can become prognostic factor by way of retrospec- tive analysis of 104 surgically resected colorectal cancer patients. Five year survival rate of 46.2% in transfusion group(n=53) is significantly decreased compared with the rate of 73.8% in non-transfusion group(n=51) (P<0.05). In subgroup analysis, there is no difference in survival rate by stage, the amount and component of blood transfusion. There are many other variables that can affect survival rate of cancer patient except for transfusion, multivariate Cox regression analysis was performed. The tumor differentiation is the greatest relative risk, but transfusion itself is not an independent prognostic value. In conclusion, perioperative transfusion and the swvival rate did not show direct relationship in these surgically resected coiorectal cancer patients. Nevertheless the difference in survival rate between transfusion group and non-transfusion group is significant, judicious use of blood products, use of frozen washed red blood cells that are totally lacking in white cells might be necessary. To confirm the direct causal relationship between perioperative transfusion and the survival in colorectal cancer, the larger prospective investigations are thought to be needed.

3,258 View
17 Download

A Phase 2 Clinical Trial of Recombinant Human Granulocyte Macrophage Colony Stimulatin: Sun Young Rha, Jae Kyung Roh, Kyung Hee Lee, Hyun Cheol Chung, Jong Inn Lee, Jin Hyuk Choi, Hye Ran Lee, Nae Chun Yoo, Joo Hang Kim, Dae Seog Heo, Jin Hyuk Choi, Ho Yeong Lim, Jee Sook Hahn, Byung So; J Korean Cancer Assoc. 1995;27(3):490-504.

Abstract PDF: Background
; Rh GM-CSF is known to stimulate the growth of granulocyte-macrophage pre- cursors and can prevent the neutropenia and infection after high dose chemotherapy. We planned to evaluate the efficacy and toxicities of rh GM-CSF and to determine the clinically recommended dose of yeast-derived rh GM-CSF(LBD-005), based on the biologicaily active doses from phase I clinical triaL Methods; Open non-randomized phase II study was carried out in 40 cancer patients with chemotherapy induced myelosuppression. After the control period(chemotherapy without rh GM-CSF), rh GM-CSF was started 24 hours after the second chemotherapy to 3 groups of patients with the doses of 150, 250, 350 ug/m(2)/d by once-daily subcutaneous admlnistration for 10 days. Resnlts; Of the 40 enrolled patients, two patients refused to be followed and. one patient couldn't finish the study due to the disease progression. So 37 patients were evaluable and the number of patients at the dose of 150, 250, 350 pg/m/d were 12, 12 and 13 petients, respectively. They were consisted of 12 with stomach cancers, 10 with breast cancers, 5 with osteosarcoma and 10 patients with other malignancies, and received chemotherapeutic agents like VP-16, cisplatinum, adriamycin. When we compared the hematologic parameters between the control and treatment periods, the mean nadir of WBC counts(/mm(3)) at the dose of 150ug/m(2)/d were 1480, 2085, each, l280, l997 at the dose of 250 ug/m/d, and 1091, 1788 at the dose of 350 ug/m(2)/d respectively. Also the recovery days of WBC counts from nadir to 4000/m(3) were improved from 8 days in control period to 4.7 days in treatment period at the dose of 150 ug/m(2)/d. There were the same results at the dose of 250 and 350 ug/m(2)/d, such as from 7.4 days to 4.4 days and from 8.5 days to 5.2 days, respectively. In view of neutrophils, we could find the same results(p<0.05). There are trends that the recovery from nadir at the dose of 250 ug/m(2)/d or more is rapid, rather than l50ug/m(2)/d. Two patients with 350ug/m(2)/d complained of severe (WHO toxicity grade III) skin reaction and chest tightness, but they tolerated well after reduction to 250 ug/m(2) /d dose. Conclasion; This study suggested the effects of yeast-derived rh GM-CSF with the dose of 1SO, 250, 350ug/m(2)/d, S.Q. for 10 days to prvent the chemotherapy induced neutropenia. And when we considered the efficacy and tolerability, 250 ug/m(2)/d is appropriate for phase III clinical triaL

2,974 View
13 Download

Search